fda compounding semaglutide warning letters september 2025 warns Novo Nordisk over GLP-1 medication side effects fda glp-1 compounding warning letters

Additionally, researchers have observed interactions with the dopaminergic and serotonergic systems in neurological models, suggesting broad signaling pathway engagement

It protects your body from disease and toxins

Because CIV has a greater affinity for NO than oxygen, NO binds to CIV instead of oxygen

Divi's Laboratories is already supplying semaglutide components globally Price compression will occur Not immediately, and not to generic-drug levels, but a ~50% reduction from current branded pricing is a reasonable baseline expectation based on biosimilar precedent in other biologic classes New formulations will compete Novo Nordisk's oral semaglutide (approved December 2025 by the FDA and launched in early 2026) and the newly FDA-approved once-daily oral GLP-1 orforglipron (Foundayo, approved April 1, 2026) represent the manufacturer's strategy for maintaining market share through innovation beyond the injectable The arrival of biosimilar competition does not mean branded products disappear